Visionary Leader Kristen Jones Letrent, PharmD, has assumed the role of Head of Late Development Oncology Clinical Science at Bristol Myers Squibb, strengthening the company’s leadership in advancing innovative oncology therapies.

In this role, Kristen will lead clinical science strategy for late-stage oncology development programs, focusing on accelerating the advancement of transformative medicines for cancer patients. She will work closely with global research, clinical development, and regulatory teams to support the successful progression of oncology treatments through late-stage clinical trials and regulatory pathways.

Kristen brings significant expertise in oncology clinical development, scientific leadership, and pharmaceutical innovation. Throughout her career, she has contributed to advancing patient-focused research and the development of therapies aimed at addressing complex and life-threatening diseases.

CXO TechBOT wishes Kristen Jones Letrent great success in her new role.